The fifth batch of national sourcing 122 pharmaceutical companies "war" is imminent

1.

According to statistics, as of June 8, the fifth batch of 58 national sourcing varieties will usher in the competition of 122 over-rated companies (calculated by the parent company)

Taking ceftazidime for injection as an example, some companies have obtained national centralized procurement tickets through consistency evaluation

According to the announcement, ceftazidime for injection is a category B product of the 2020 National Medical Insurance and a 2018 version of the National Essential Drug List.

It can be seen from the announcement of the company that it is highly important to step into the fifth batch of national centralized procurement enterprises.

In terms of the competition pattern of varieties, as more and more companies have been reviewed, the competition has become increasingly fierce

From the perspective of pharmaceutical companies, in the fifth batch of national collections, Qilu Pharmaceuticals and China Biopharmaceuticals have the largest number of reviews, both of which have 13 varieties selected; followed by Yangzijiang Pharmaceuticals (12 types of drugs), Kelun Pharmaceuticals (11 varieties), Hengrui Pharmaceuticals (7 varieties), Chengdu Beite (6 varieties), Aosaikang (6 varieties), Hausen Pharmaceutical (5 varieties), Lunan Pharmaceutical (4 varieties) Varieties), Haisco (4 varieties)

Reviewing the results of the fourth batch of national selection, we can find that China's biopharmaceutical products have an average decline of -70.

In addition, judging from the fact that the overall average decline of the first four batches of national centralized procurement has reached 50%, it is possible to predict the quotation on June 23 in advance, and it is estimated that the price reduction is not low

2.

According to GBI statistics, according to the status of the shortlisted products of all foreign-funded pharmaceutical companies in the past, Pfizer, AstraZeneca, and Novartis have the largest number of finalists (according to product specifications), at 23, 20, and 14, respectively

In terms of winning bids for foreign-funded pharmaceutical companies, according to Cyberlan, only two foreign companies won the bids in the 4+7 pilot program.

The fifth batch of national centralized procurement that will be settled on June 23, the participation of foreign pharmaceutical companies has also brought many expectations and reveries to the industry

3.

At the end of the article, I would like to review some of the key points of the fifth batch of national collections
.

Deadline and place for submission of application materials: June 23, 2021 (Wednesday) at 8 o'clock in the morning to receive application materials
.
Deadline for submission: June 23, 2021 (Wednesday) at 10 am
.
Time and place for the disclosure of the declared information: June 23, 2021 (Wednesday) at 10 am
.
Supply area confirmation time and place: June 23, 2021 (Wednesday) at 2 pm
.

According to the procurement documents, the fifth batch of national procurement finalists are the same as the fourth batch, allowing up to 10 finalists
.
That is, 3 enters 2, 4 enters 3, 5 enters 4, 6 enters 4, 7 enters 5, 8 enters 6, 9 enters 7, 10 enters 8, 11 enters 9, 12 enters 9, if more than 13, the maximum number of shortlisted companies For 10 companies
.

There are three conditions for determining the criteria for the company to be selected:

1.
The quotation is not higher than 1.
8 times of the lowest quotation; 2.
The decrease is not less than 50%; 3.
The quotation is not higher than 0.
1 yuan
.

The shortlisted manufacturers can be selected as long as they meet one of the above three conditions
.

In view of the fact that some products have already been reviewed by many pharmaceutical companies, everyone in the pharmaceutical industry must prepare in advance and make scientific quotations to welcome the arrival of a "hard battle"
.